High Dose Daunorubicin Improves Survival In Aml Up To Age 60, Across All Cytogenetic Risk Groups Including Patients With Unfavorable Cytogenetic Risk, And Flt3-Itd Mutant Aml: Updated Analyses From Eastern Cooperative Oncology Trial E1900

BLOOD(2014)

引用 29|浏览18
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要